Eva Muñoz‐Couselo

5.0k citations
92 papers · 2.2k · 2 hit papers · h-index 21

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Cancer Cells and Metastasis
    • HER2/EGFR in Cancer Research
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 42
    • CAR-T cell therapy research 18
    • Cutaneous Melanoma Detection and Management 12
    • HER2/EGFR in Cancer Research 7
    • Melanoma and MAPK Pathways 24

Eva Muñoz‐Couselo

81 papers receiving 2.2k citations

Eva Muñoz‐Couselo's Hit Papers

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial 2021 · 352 citations
3520+2+4Years since publication100200300

Peers

Eva Muñoz‐Couselo
Comparison fields: 5 of 74
  • Oncology 1.5k
  • Cancer Research 370
  • Immunology 507
  • Pulmonary and Respiratory Medicine 303
  • Molecular Biology 530
Replace Maria Toki with:
Maria Toki United States
Kamila Naxerova United States
Elisa Espinet Germany
Guichun Huang China
Akhil Chawla United States
Ngocdiep T. Le United States
Ariel López-Chávez United States
Hanno Matthaei Germany
Patrick G. Pilié United States
Andreas Schneeweiss United States
Eva Muñoz‐Couselo relative to Maria Toki United States Maria Toki's profile →
Citations per field
00.5×
Maria Toki · 1×
Citations per year

Countries citing papers authored by Eva Muñoz‐Couselo

Since Specialization
Citations

This map shows the geographic impact of Eva Muñoz‐Couselo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Muñoz‐Couselo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Muñoz‐Couselo more than expected).

Fields of papers citing papers by Eva Muñoz‐Couselo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Muñoz‐Couselo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Muñoz‐Couselo. The network helps show where Eva Muñoz‐Couselo may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Muñoz‐Couselo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Muñoz‐Couselo Line = papers co-authored together Eva Muñoz‐Couselo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2021352
2
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Hit paper breakdown →
2020298
3 2017198
4 2017122
5 2011121
6 2018100
7 201784
8 201768
9 201566
10 201962
11 202052
12 202049
13 201844
14 202336
15 202235
16 202030
17 202129
18 201829
19 201522
20 201022

About Eva Muñoz‐Couselo

Eva Muñoz‐Couselo is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 92 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (42 papers), Melanoma and MAPK Pathways (24 papers), CAR-T cell therapy research (18 papers), Cutaneous Melanoma Detection and Management (12 papers), Cancer Genomics and Diagnostics (11 papers), Immunotherapy and Immune Responses (10 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (7 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (370 citations), Immunology (507 citations), Pulmonary and Respiratory Medicine (303 citations) and Molecular Biology (530 citations). Eva Muñoz‐Couselo has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Javier Cortés, José Manuel Pérez-García, Seock‐Ah Im, Carolina Ortiz, Vassiliki Karantza, Rebecca Dent, Peter Schmid, Joohyuk Sohn, Theodoros Foukakis and Isabell Witzel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical & Translational Oncology, Cancer Research and OncoTargets and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact